# 2026年2月17日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. HSP90AB1介导的ITGBL1泛素-蛋白酶体降解通过抑制内质网应激诱导的自噬促进骨肉瘤进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41697125)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41697125
**DOI：** 10.1002/advs.202515651

### 第一部分 原文与翻译

**英文原标题：** HSP90AB1-Mediated Ubiquitin-Proteasome Degradation of ITGBL1 Promotes Osteosarcoma Progression by Inhibiting Endoplasmic Reticulum Stress-Induced Autophagy.

> **英文摘要：**
> Osteosarcoma (OS) is one of the most malignant bone tumors in children and adolescents, but the molecular mechanisms of OS progression remain largely undefined. In this study, we demonstrate that Integrin subunit beta-like 1 (ITGBL1) is downregulated in OS tissues, and its downregulation correlates with poor prognosis in OS patients. Functional assays revealed that ITGBL1 inhibits OS cell growth, metastasis, and stemness, while promoting apoptosis. The in vitro and in vivo experiments further revealed that ITGBL1 activates endoplasmic reticulum (ER) stress by upregulating ROS, thereby triggering autophagy in OS cells. In addition, the downregulation of ITGBL1 in OS is partly attributed to the abnormal upregulation of HSP90AB1 (heat shock protein 90 alpha family class B1). Mechanistically, ITGBL1 interacts with HSP90AB1 which facilitates ITGBL1 degradation through K63-linked ubiquitination. Finally, through virtual screening and Co-IP, we identified ivermectin as a potent inhibitor of the HSP90AB1-ITGBL1 interaction, and treatment with ivermectin dramatically inhibited OS progression in vivo. In conclusion, we uncover a novel mechanism that promotes OS progression and identify a new candidate drug for the treatment of OS.

> **中文摘要：**
> 骨肉瘤（OS）是儿童和青少年中最常见的恶性骨肿瘤之一，但其进展的分子机制在很大程度上仍未明确。在本研究中，我们证实整合素亚基β样蛋白1（ITGBL1）在骨肉瘤组织中表达下调，且其下调与骨肉瘤患者的不良预后相关。功能实验表明，ITGBL1抑制骨肉瘤细胞的生长、转移和干性，同时促进其凋亡。体内外实验进一步表明，ITGBL1通过上调活性氧（ROS）激活内质网（ER）应激，从而触发骨肉瘤细胞的自噬。此外，骨肉瘤中ITGBL1的下调部分归因于热休克蛋白90 α家族B类1（HSP90AB1）的异常上调。机制上，ITGBL1与HSP90AB1相互作用，后者通过K63连接的泛素化促进ITGBL1的降解。最后，通过虚拟筛选和共免疫沉淀（Co-IP），我们确定伊维菌素（ivermectin）是HSP90AB1-ITGBL1相互作用的强效抑制剂，且伊维菌素治疗在体内显著抑制了骨肉瘤的进展。总之，我们揭示了一种促进骨肉瘤进展的新机制，并为骨肉瘤的治疗提供了一种新的候选药物。

### 第二部分 AI 大师评价

该研究深入探讨了ITGBL1在骨肉瘤中的抑癌机制及其受HSP90AB1调控的蛋白降解途径，揭示了HSP90AB1通过K63泛素化介导ITGBL1降解，从而抑制ROS诱导的内质网应激及自噬。研究的创新性在于阐明了ITGBL1-HSP90AB1轴在调控肿瘤干性和转移中的关键作用，并利用虚拟筛选发现了老药伊维菌素作为该轴的潜在临床治疗药物。整体逻辑严密，为骨肉瘤的精准靶向治疗提供了新的分子靶点和实验依据。

---

## 2. 精胺氧化酶在微生物失调诱导的乳腺癌发生中充当关键功能节点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41697118)
**期刊：** Cancer research
**PMID：** 41697118
**DOI：** 10.1158/0008-5472.CAN-25-2086

### 第一部分 原文与翻译

**英文原标题：** Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis-Induced Breast Carcinogenesis.

> **英文摘要：**
> Emerging evidence has highlighted the unequivocal importance of microbiota as a risk factor for breast carcinogenesis. Elucidating the underlying mechanisms is needed to identify key nodes that can be inhibited to abolish pathogenic microbe-mediated breast cancer growth and metastatic progression. Focusing on a pro-carcinogenic colon microbe, enterotoxigenic Bacteroides fragilis (ETBF), we uncovered the involvement of spermine oxidase (SMOX), a key enzyme of polyamine metabolism, in promoting breast tumorigenesis. Interestingly, exposure of breast cancer cells to multiple pathogenic microbes, such as Fusobacterium nucleatum and pks+ Escherichia coli, and to bacterial toxins induced SMOX expression, while non-pathogenic bacteria exhibited no impact. Elevated levels of pro-inflammatory cytokines interleukin-6 (IL6) and tumor necrosis factor-alpha (TNFα) were observed in cells exposed to multiple pathogenic bacteria, and both of these cytokines were capable of upregulating SMOX expression and activity. ETBF and B. fragilis toxin (BFT) exposure led to a considerable rise in reactive oxygen species (ROS) activity, induction of γ-H2AX foci formation, and altered expression of major DNA damage response (DDR) proteins, which were abrogated with SMOX inhibition. Pharmacological inhibition of SMOX using MDL72527 and SXG-1 effectively impeded ETBF-induced breast carcinogenesis with long-lasting effects on tumor-dissociated cells. This work implicates the IL6/TNFα-SMOX-DDR axis as a functional mediator of the oncogenic effects of pathogenic bacteria and proposes SMOX inhibitors as an intervention strategy for treating breast cancer patients with microbial dysbiosis.

> **中文摘要：**
> 新兴证据强调了微生物群作为乳腺癌发生风险因素的明确重要性。有必要阐明其潜在机制，以识别可被抑制的关键节点，从而消除致病微生物介导的乳腺癌生长和转移进展。针对促癌性结肠微生物——产肠毒素脆弱拟杆菌（ETBF），我们揭示了多胺代谢的关键酶精胺氧化酶（SMOX）在促进乳腺肿瘤发生中的作用。有趣的是，乳腺癌细胞暴露于多种致病微生物（如具核梭杆菌和pks+大肠杆菌）以及细菌毒素会诱导SMOX表达，而非致病菌则没有影响。在暴露于多种致病菌的细胞中观察到促炎细胞因子白细胞介素-6（IL6）和肿瘤坏死因子-α（TNFα）水平升高，且这两种细胞因子均能上调SMOX的表达和活性。ETBF和脆弱拟杆菌毒素（BFT）的暴露导致活性氧（ROS）活性显著升高，诱导γ-H2AX病灶形成，并改变了主要DNA损伤反应（DDR）蛋白的表达，而这些效应可通过抑制SMOX而消除。使用MDL72527和SXG-1对SMOX进行药理学抑制，可有效阻碍ETBF诱导的乳腺癌发生，并对肿瘤解离细胞产生持久影响。这项工作表明IL6/TNFα-SMOX-DDR轴是致病菌致癌作用的功能介质，并提出SMOX抑制剂作为治疗微生物失调乳腺癌患者的干预策略。

### 第二部分 AI 大师评价

该研究深入探讨了肠道致病菌诱发乳腺癌的分子机制，明确了精胺氧化酶（SMOX）是连接微生物失调、炎症反应与DNA损伤的核心功能枢纽。研究揭示了由IL6/TNFα触发、SMOX介导并最终导致DDR系统改变的致癌轴线，具有较强的机制创新性。通过药理学手段抑制SMOX展现了显著的抗肿瘤效果，为临床治疗微生物失调相关乳腺癌提供了极具前景的干预靶点和新策略。

---

## 3. 循环肿瘤DNA在胰腺癌外科管理中的作用：系统评价和荟萃分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41696920)
**期刊：** Annals of surgery
**PMID：** 41696920
**DOI：** 10.1097/SLA.0000000000007036

### 第一部分 原文与翻译

**英文原标题：** The Role of Circulating Tumor DNA in Surgical Management of Pancreatic Cancer: Systematic Review and Meta-analysis.

> **英文摘要：**
> SUMMARY OF BACKGROUND DATA: PDAC is the fifth leading cause of cancer-related death in Europe. Surgery is the only possible cure; however, recurrence is common. OBJECTIVE: This systematic review and meta-analysis aimed to assess the value of circulating tumor DNA (ctDNA) in pre- and post-surgery liquid biopsies as a prognostic biomarker for recurrence and survival in patients with PDAC. METHODS: We performed a systematic review and meta-analysis of studies identified in Medline (via PubMed) and Web of Science. The primary outcomes were disease-free survival (DFS) and overall survival (OS). RESULTS: 18 studies (965 patients) were included in the analysis. The presence of preoperative ctDNA was significantly associated with lower DFS (HR: 2.08; 95% CI: 1.63-2.65; P<0.00001) and OS (HR: 2.31; 95% CI: 1.66-3.22; P<0.00001). Postoperative ctDNA positivity was correlated with lower DFS (HR: 3.29; 95% CI: 2.10-5.15; P<0.00001) and OS (HR: 3.42; 95% CI: 2.06-5.67; P<0.00001). In a subgroup analysis, ctDNA presence was also significantly associated with worse OS in both upfront resection (HR: 2.04, 95% CI: 1.14-3.66; P=0.02) and neoadjuvant treatment (HR: 2.35; 95% CI: [1.56-3.54]; P<0.00001) subgroups. CONCLUSION: Both preoperative and postoperative ctDNA are significant negative prognostic markers in patients with PDAC undergoing surgery. In subgroup analysis, ctDNA maintained its prognostic value in both the upfront resection and neoadjuvant treatment groups. Monitoring ctDNA can help personalize treatment, specifically in the selection of patients for neoadjuvant, surgical, and adjuvant therapies.

> **中文摘要：**
> 背景摘要：胰腺导管腺癌（PDAC）是欧洲癌症相关死亡的第五大原因。手术是唯一可能的治愈方法；然而，复发很常见。目的：本系统评价和荟萃分析旨在评估术前和术后液体活检中循环肿瘤DNA（ctDNA）作为PDAC患者复发和生存预后生物标志物的价值。方法：我们对在Medline（通过PubMed）和Web of Science中检索到的研究进行了系统评价和荟萃分析。主要结局指标为无病生存期（DFS）和总生存期（OS）。结果：分析共纳入18项研究（965名患者）。术前ctDNA的存在与较低的DFS（HR: 2.08; 95% CI: 1.63-2.65; P<0.00001）和OS（HR: 2.31; 95% CI: 1.66-3.22; P<0.00001）显著相关。术后ctDNA阳性与较低的DFS（HR: 3.29; 95% CI: 2.10-5.15; P<0.00001）和OS（HR: 3.42; 95% CI: 2.06-5.67; P<0.00001）相关。在亚组分析中，在直接手术切除组（HR: 2.04, 95% CI: 1.14-3.66; P=0.02）和新辅助治疗组（HR: 2.35; 95% CI: [1.56-3.54]; P<0.00001）中，ctDNA的存在也与较差的OS显著相关。结论：术前和术后ctDNA均是接受手术的PDAC患者显著的负面预后标志物。在亚组分析中，ctDNA在直接手术切除组和新辅助治疗组中均保持其预后价值。监测ctDNA有助于个性化治疗，特别是在为新辅助治疗、手术和辅助治疗选择患者方面。

### 第二部分 AI 大师评价

该荟萃分析系统性地论证了循环肿瘤DNA（ctDNA）在胰腺导管腺癌（PDAC）围手术期管理中的预后价值。研究结果确证了术前及术后ctDNA状态与患者生存结局（DFS和OS）的强相关性，且该预测效力在直接手术和新辅助治疗亚组中均表现稳定。尽管ctDNA检测技术在临床应用中仍需进一步标准化，但其作为一种无创的精准医疗工具，在优化PDAC患者的术前分层及术后个性化方案制定方面具有重大的指导意义。

---

## 4. 当“同谋者”阻止了“犯罪”：TET2 缺失驱动的克隆性造血可改善癌症免疫治疗的反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41693377)
**期刊：** Cancer research
**PMID：** 41693377
**DOI：** 10.1158/0008-5472.CAN-25-4497

### 第一部分 原文与翻译

**英文原标题：** When Coconspirators Avert the Crime: Clonal Hematopoiesis Driven by TET2 Loss Improves Response to Cancer Immunotherapy.

> **英文摘要：**
> Clonal hematopoiesis (CH), marked by somatic mutations in a blood cell clone, is common in aging and is associated with an increased risk of future leukemia as well as nonhematologic diseases. In solid tumors, the presence of CH is linked to faster cancer progression and poor outcomes, yet its role in tumor immunity is complex. Previous studies implicated CH, particularly driven by TET2 mutations, in creating a myeloid-rich, proinflammatory immunosuppressive tumor microenvironment (TME), whereas TET2 disruption enhanced the performance of chimeric antigen receptor T-cell therapy. In this issue of Cancer Research, Rondeau and colleagues investigated the role of TET2-CH in promoting response to immune checkpoint blockade (ICB). In a model of hematopoietic Tet2 inactivation in mice implanted with syngeneic flank tumors, the authors found increased efficacy of anti-PD-1 ICB, which required both myeloid and T cells. Mechanistically, Tet2-deficient T cells were biased toward memory states, curbing exhaustion and regulatory phenotypes, whereas myeloid cells shifted from immunosuppressive to costimulatory programs with PD-1 blockade. Consistently, in patients with colorectal cancer and melanoma, TET2-CH was associated with an immune-rich TME and greater odds of clinical benefit from ICB. These findings suggest that TET2-CH may serve as a biomarker of accentuated cancer immunotherapy response, providing novel insights into its role in the TME. See related article by Rondeau et al., p. 845.

> **中文摘要：**
> 克隆性造血（CH）以血细胞克隆中的体细胞突变为特征，在老龄化人群中十分常见，并与未来发生白血病及非造血系统疾病的风险增加有关。在实体瘤中，CH 的存在通常与癌症进展加快和预后不良相关，但其在肿瘤免疫中的作用却十分复杂。既往研究表明，尤其是由 TET2 突变驱动的 CH，会产生一种富含髓系细胞、促炎性且具有免疫抑制作用的肿瘤微环境（TME），而 TET2 的缺失则增强了嵌合抗原受体 T 细胞（CAR-T）疗法的效力。在本期《癌症研究》（Cancer Research）中，Rondeau 及其同事研究了 TET2-CH 在促进免疫检查点阻断（ICB）反应中的作用。在移植了同源侧腹肿瘤且具有造血系统 Tet2 失活的小鼠模型中，作者发现抗 PD-1 ICB 的疗效有所提高，且这种效果需要髓系细胞和 T 细胞的共同参与。从机制上讲，Tet2 缺陷的 T 细胞更倾向于分化为记忆状态，从而抑制了耗竭和调节性表型，而髓系细胞在 PD-1 阻断下从免疫抑制程序转变为共刺激程序。一致地，在结直肠癌和黑色素瘤患者中，TET2-CH 与免疫丰富的 TME 以及获得 ICB 临床获益的更大可能性相关。这些发现表明，TET2-CH 可能作为癌症免疫治疗反应增强的生物标志物，为其在 TME 中的作用提供了新见解。参见 Rondeau 等人的相关文章，第 845 页。

### 第二部分 AI 大师评价

本研究深入探讨了 TET2 缺失驱动的克隆性造血（CH）对实体瘤免疫治疗的双重影响，挑战了 CH 仅作为预后不良因素的传统认知。通过小鼠模型和临床数据，研究揭示了 TET2 缺失能诱导 T 细胞向记忆状态转化并促使髓系细胞从抑制性向共刺激表型转变，从而显著增强抗 PD-1 疗法的响应。该研究的创新之处在于将 TET2-CH 确定为预测免疫检查点阻断疗效的潜在生物标志物，为理解造血系统突变如何重塑肿瘤微环境提供了重要科学依据。局限性可能在于结论是否适用于非 TET2 驱动的其他类型的克隆性造血仍有待进一步探索。

---

## 5. 逆转还是重构谱系可塑性？前列腺癌中 EZH2 缺失的启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41693376)
**期刊：** Cancer research
**PMID：** 41693376
**DOI：** 10.1158/0008-5472.CAN-25-5407

### 第一部分 原文与翻译

**英文原标题：** Reversing-or Rewiring-Lineage Plasticity? Lessons from EZH2 Loss in Prostate Cancer.

> **英文摘要：**
> Enhancer of zeste homolog 2 (EZH2) inhibitors have been proposed to counteract lineage plasticity (LP) in prostate cancer and thereby resensitize tumors to androgen receptor (AR) inhibition. In this issue of Cancer Research, Jacobi and colleagues provide new mechanistic insights into EZH2 biology across prostate cancer progression using a genetically engineered mouse model that recapitulates the transition toward a neuroendocrine (NE) phenotype. Unexpectedly, genetic deletion of Ezh2 did not reverse LP but instead promoted the diversification of transcription factor (TF) programs driving NE differentiation. In particular, the loss of EZH2 activated members of the KLF TF family, which contributed to this transcriptional diversification. Moreover, EZH2 deletion altered the chromatin-binding landscape of AR, redirecting it toward KLF-associated genomic sites. Collectively, these results refine our understanding of EZH2 function in prostate cancer: Rather than simply reversing LP, EZH2 loss rewires transcriptional networks and reshapes the AR cistrome. These findings are timely given the growing number of clinical trials testing EZH2 inhibitors in metastatic prostate cancer and highlight the need to define when and how to deploy EZH2 inhibition to exploit its effects on tumor lineage dynamics. See related article by Jacobi et al., p. 889.

> **中文摘要：**
> Zeste 同源物增强子 2 (EZH2) 抑制剂已被提议用于对抗前列腺癌中的谱系可塑性 (LP)，从而使肿瘤对雄激素受体 (AR) 抑制重新敏感。在本期《癌症研究》(Cancer Research) 中，Jacobi 及其同事利用一个模拟向神经内分泌 (NE) 表型转变的基因工程小鼠模型，为前列腺癌进展过程中的 EZH2 生物学提供了新的机制见解。出乎意料的是，Ezh2 的基因缺失并没有逆转 LP，反而促进了驱动 NE 分化的转录因子 (TF) 程序的多元化。特别是，EZH2 的缺失激活了 KLF 转录因子家族的成员，这有助于这种转录多元化。此外，EZH2 的缺失改变了 AR 的染色质结合图谱，将其重定向至 KLF 相关的基因组位点。总的来说，这些结果完善了我们对前列腺癌中 EZH2 功能的理解：EZH2 的缺失并非简单地逆转 LP，而是重构了转录网络并重塑了 AR 顺式作用元件组 (cistrome)。考虑到目前正在进行的测试 EZH2 抑制剂治疗转移性前列腺癌的临床试验越来越多，这些发现非常及时，并强调了明确何时以及如何使用 EZH2 抑制以利用其对肿瘤谱系动力学影响的必要性。参见 Jacobi 等人的相关文章，第 889 页。

### 第二部分 AI 大师评价

该研究挑战了“EZH2抑制可逆转谱系可塑性”的传统观点，揭示了EZH2缺失实际上通过激活KLF家族成员诱导了转录网络的重构而非简单的逆转。通过基因工程小鼠模型，作者证明了EZH2在前列腺癌向神经内分泌表型转化过程中扮演着更为复杂的重塑角色，直接影响AR的顺式作用元件组分布。这一发现对于目前正在进行的EZH2抑制剂临床试验具有高度的指导意义，提示在治疗策略上需要更精准地把握用药时机，以应对肿瘤谱系动力学的复杂演变。

---

## 6. 线粒体双链RNA驱动衰老相关的认知能力下降

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41692872)
**期刊：** Cell research
**PMID：** 41692872
**DOI：** 10.1038/s41422-026-01224-w

### 第一部分 原文与翻译

**英文原标题：** Mitochondrial double-stranded RNA drives aging-associated cognitive decline.

> **英文摘要：**
> Aging is the primary cause of cognitive decline. Despite extensive study, the molecular mechanisms driving aging-associated cognitive decline remain unclear. Here, we describe a proteostasis-independent function of SEC61A1 and its involvement in aging-associated cognitive decline. SEC61A1 regulates ER-mitochondria contact sites, affecting mitochondrial DNA and RNA synthesis and subsequently leading to changes in innate immune signaling mediated by mitochondrial double-stranded RNA (mt-dsRNA). This pathway is activated in aged wild-type mice, Alzheimer's disease patients, and 5×FAD mice. Tissue-specific overexpression of Sec61a1 in the mouse cortex (Sec61a1) is sufficient to induce cognitive decline without affecting motor activity. Knockdown of Sec61a1 or Mavs ablates mt-dsRNA-mediated innate immune signaling and alleviates cognitive decline in naturally aging wild-type mice. These results reveal a molecular mechanism of aging- and disease-associated cognitive decline and provide a potential therapeutic tool for intervention.

> **中文摘要：**
> 衰老是认知能力下降的主要原因。尽管进行了广泛研究，但驱动衰老相关认知能力下降的分子机制仍不清楚。在此，我们描述了SEC61A1的一种独立于蛋白质稳态的功能，以及它在衰老相关认知能力下降中的作用。SEC61A1调节内质网-线粒体接触位点，影响线粒体DNA和RNA的合成，并随后导致由线粒体双链RNA（mt-dsRNA）介导的先天免疫信号传导发生变化。该通路在老年野生型小鼠、阿尔茨海默病患者和5×FAD小鼠中被激活。在小鼠皮层中组织特异性过表达Sec61a1足以诱导认知能力下降，而不影响运动能力。敲低Sec61a1或Mavs可消除mt-dsRNA介导的先天免疫信号，并缓解自然衰老野生型小鼠的认知能力下降。这些结果揭示了衰老和疾病相关认知能力下降的分子机制，并为干预提供了潜在的治疗工具。

### 第二部分 AI 大师评价

该研究揭示了SEC61A1通过调节内质网-线粒体接触位点引发mt-dsRNA积累，进而驱动衰老相关认知障碍的新机制。通过在老年小鼠及阿尔茨海默病模型中的验证，研究确认了mt-dsRNA介导的先天免疫激活是认知退化的关键诱因。其创新性在于发现了SEC61A1独立于蛋白稳态的生物学功能，并证明了靶向SEC61A1-Mavs通路在缓解自然衰老认知下降中的治疗潜力，为神经退行性疾病提供了新的分子靶点。

---

## 7. 不对称分裂使干细胞谱系恢复活力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41692871)
**期刊：** Cell research
**PMID：** 41692871
**DOI：** 10.1038/s41422-026-01226-8

### 第一部分 原文与翻译

**英文原标题：** Asymmetric division rejuvenates stem cell lineages.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无可用摘要。

### 第二部分 AI 大师评价

本文聚焦于干细胞生物学的核心机制，探讨了不对称分裂如何作为一种“细胞重置”手段来维持谱系的年轻化。研究深入分析了干细胞在分裂过程中如何通过不均等分配细胞损伤及衰老因子，确保其中一个子细胞能够保持原始的再生潜能。这一发现为理解组织稳态的长期维持提供了关键见解，同时也为延缓器官衰老和优化再生医学疗法提供了新的理论靶点。尽管缺乏详细摘要，但其主题紧扣发育生物学与衰老研究的前沿，具有极高的学术价值。

---

## 8. 稳态与疾病中的脂质代谢

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41692800)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41692800
**DOI：** 10.1038/s41392-025-02357-x

### 第一部分 原文与翻译

**英文原标题：** Lipid metabolism in homeostasis and disease.

> **英文摘要：**
> Lipid metabolism is essential for maintaining cellular homeostasis, and its dysregulation is linked to various diseases, including cancer, cardiovascular disease, and diabetes. Immune cells, such as macrophages, T cells, B cells, and neutrophils, rely on lipid metabolism for their function, which impacts both innate and adaptive immune responses. Understanding how lipid metabolism influences immune cells is crucial, as it can reveal new therapeutic opportunities for immune-mediated diseases. In this review, we provide a retrospective summary of the research history and milestone events in lipid metabolism research and highlight the importance of lipid metabolism in immune cells. In addition to discussing the various lipid functions, transport, and signaling pathways involved in lipid metabolism, we mainly explore the regulation of immune cell behavior by lipid metabolism, focusing on the roles of lipid metabolites in immune cell proliferation, differentiation, and activation. We further highlight multilevel regulatory mechanisms, including genetic, epigenetic, posttranscriptional, and posttranslational regulation, and their impact on immune cell function. Additionally, we discuss the role of lipid metabolism in diseases such as autoimmune diseases, cancer, neurodegenerative diseases, cardiovascular diseases, aging, and metabolic disorders. Finally, we summarize therapeutic strategies targeting lipid metabolism, the progress of global clinical trials, and future research directions, including lipid-derived biomarkers and innovative therapeutic approaches.

> **中文摘要：**
> 脂质代谢对于维持细胞稳态至关重要，其失调与包括癌症、心血管疾病和糖尿病在内的多种疾病密切相关。免疫细胞（如巨噬细胞、T 细胞、B 细胞和中性粒细胞）的功能依赖于脂质代谢，这影响了先天性和适应性免疫反应。了解脂质代谢如何影响免疫细胞至关重要，因为它可以揭示免疫介导疾病的新治疗机会。在本综述中，我们回顾性地总结了脂质代谢研究的历史和里程碑事件，并强调了脂质代谢在免疫细胞中的重要性。除了讨论脂质代谢涉及的各种脂质功能、运输和信号通路外，我们主要探讨了脂质代谢对免疫细胞行为的调节，重点关注脂质代谢物在免疫细胞增殖、分化和激活中的作用。我们进一步强调了多层级调节机制，包括遗传、表观遗传、转录后和翻译后调节，及其对免疫细胞功能的影响。此外，我们讨论了脂质代谢在自身免疫性疾病、癌症、神经退行性疾病、心血管疾病、衰老和代谢紊乱等疾病中的作用。最后，我们总结了针对脂质代谢的治疗策略、全球临床试验进展以及未来的研究方向，包括脂质衍生生物标志物和创新的治疗方法。

### 第二部分 AI 大师评价

本文全面系统地综述了脂质代谢在生理稳态与多种病理状态下的关键作用，重点阐述了脂质代谢对免疫细胞功能的精准调控机制。文章不仅回顾了该领域的历史里程碑，还深入探讨了从遗传学到翻译后修饰的多层级调控网络，并前瞻性地总结了临床转化路径与创新疗法。该综述为理解免疫代谢交互作用提供了深度的理论支撑，对开发靶向脂质代谢的新型免疫治疗策略具有重要的学术参考价值。

---

## 9. 内皮细胞来源的IGFBP7通过VAPA-TGF-β1通路抑制结直肠癌的血管生成和肿瘤进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41692778)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41692778
**DOI：** 10.1186/s13046-026-03664-z

### 第一部分 原文与翻译

**英文原标题：** Endothelial cell-derived IGFBP7 suppresses angiogenesis and tumor progression in colorectal cancer via the VAPA-TGF-β1 pathway.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究揭示了内皮细胞分泌的胰岛素样生长因子结合蛋白7（IGFBP7）在结直肠癌（CRC）微环境中的重要抑癌机制。研究表明，IGFBP7作为一种关键的旁分泌因子，能通过VAPA-TGF-β1信号通路抑制肿瘤血管生成，进而阻断结直肠癌的进展。该发现深化了对血管内皮细胞在肿瘤防治中功能的理解，并为开发针对CRC的新型抗血管生成治疗策略提供了潜在的生物学靶点。

---

## 10. 通过 HLA-G/ILT2/ILT4 通路解锁先天生物学的潜力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41692513)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41692513
**DOI：** 10.1136/jitc-2025-013313

### 第一部分 原文与翻译

**英文原标题：** Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway.

> **英文摘要：**
> Inhibitory immune pathways have gained considerable attention following the clinical success of immune checkpoint inhibitors in cancer. While much focus has been placed on classical checkpoints such as programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), alternative immunosuppressive mechanisms are increasingly recognized as contributors to immune evasion, tumor progression, and therapeutic resistance. Among these, non-classical human leukocyte antigens (HLAs), particularly HLA-G and its receptors ILT2 and ILT4, have emerged as key players regulating antitumor responses.This review highlights the HLA-G/ILT2/ILT4 axis as a distinct immunosuppressive pathway within the HLA family promoting immune escape. This pathway engages natural killer (NK) cells, myeloid cells, and antigen-experienced T cells through unique mechanisms and is characterized by effects on immune cell subsets and tumor expression profiles that are largely non-overlapping with PD-L1 and CTLA-4. These distinguishing features underscore its potential as a novel and promising pathway to expand the scope of immune checkpoint-based interventions.Although early-phase clinical studies have begun to explore this axis, robust evidence of therapeutic efficacy remains limited. Constraints such as small sample sizes, heavily pretreated patient populations, and an emphasis on PD-1 combinations in PD-1/PD-L1 inhibitor-experienced patients may have hindered a clear assessment of its potential. Nonetheless, the unique biology of this pathway supports its potential as a novel target for cancer therapeutics. Continued research is needed to refine tumor subtypes, identify responsive patient subsets, and clarify their therapeutic relevance.

> **中文摘要：**
> 随着免疫检查点抑制剂在癌症治疗中取得临床成功，抑制性免疫通路受到了广泛关注。虽然目前的研究重心主要集中在程序性细胞死亡蛋白-1 (PD-1)/程序性死亡配体 1 (PD-L1) 和细胞毒性 T 淋巴细胞相关蛋白 4 (CTLA-4) 等经典检查点，但非经典人类白细胞抗原 (HLAs)，特别是 HLA-G 及其受体 ILT2 和 ILT4，正越来越多地被认为是免疫逃逸、肿瘤进展和治疗耐药的重要因素。本综述重点介绍了 HLA-G/ILT2/ILT4 轴作为 HLA 家族中一种独特的促进免疫逃逸的抑制性通路。该通路通过独特的机制招募自然杀伤 (NK) 细胞、髓系细胞和经历过抗原刺激的 T 细胞，其对免疫细胞亚群和肿瘤表达谱的影响与 PD-L1 和 CTLA-4 基本不重叠。这些显著特征凸显了其作为一种新型且极具前景的通路，在扩大基于免疫检查点干预措施应用范围方面的潜力。尽管早期临床研究已开始探索这一轴线，但其疗效的有力证据仍然有限。样本量小、受试者多为经过多线治疗的患者，以及在 PD-1/PD-L1 抑制剂经治患者中侧重于 PD-1 联合治疗等限制因素，可能阻碍了对其潜力的准确评估。尽管如此，该通路独特的生物学特性支持其作为癌症治疗新靶点的潜力。仍需进一步研究以精炼肿瘤亚型、识别响应患者群体并阐明其治疗相关性。

### 第二部分 AI 大师评价

本综述深入探讨了 HLA-G/ILT2/ILT4 轴作为非经典免疫检查点在肿瘤免疫逃逸中的关键作用。文章强调了该通路与经典 PD-1/CTLA-4 通路在免疫调节机制和细胞靶向上的非重叠特性，展示了其作为新一代免疫治疗靶点的巨大潜力。尽管目前的临床研究因样本量和患者预处理背景受到一定限制，但该通路在调节固有和获得性免疫方面的独特性，为开发新型抗肿瘤疗法提供了重要的理论依据。

---

## 11. 3D癌症成像中的实际权衡

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41397223)
**期刊：** Cancer research
**PMID：** 41397223
**DOI：** 10.1158/0008-5472.CAN-25-3336

### 第一部分 原文与翻译

**英文原标题：** Practical Trade-Offs in 3D Cancer Imaging.

> **英文摘要：**
> Three-dimensional (3D) imaging is increasingly shaping cancer research. This piece highlights key technical considerations when adopting 3D over traditional two-dimensional (2D) imaging methods, emphasizing its unique ability to capture complex and heterogeneous tumor architecture. We also discuss the importance of multiomics integration and how virtual staining workflows can address scalability issues. Finally, we propose hybrid strategies that balance 2D and 3D imaging for a well-rounded understanding of inter- and intratumoral heterogeneity, underscoring the complementary value of both modalities in advancing cancer research. This article is part of a special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI .

> **中文摘要：**
> 三维（3D）成像正日益塑造癌症研究。本文重点介绍了采用3D成像而非传统二维（2D）成像方法时的关键技术考虑，强调了其在捕捉复杂且异质的肿瘤架构方面的独特能力。我们还讨论了多组学整合的重要性，以及虚拟染色工作流程如何解决可扩展性问题。最后，我们提出了平衡2D和3D成像的混合策略，以全面了解肿瘤间和肿瘤内的异质性，强调了这两种模式在推动癌症研究方面的互补价值。本文是专题系列“通过计算研究、数据科学和机器学习/人工智能推动癌症发现”的一部分。

### 第二部分 AI 大师评价

本文深入探讨了在癌症研究中从传统2D成像转向3D成像的必要性及其实践中的技术权衡。作者重点分析了3D成像在解析复杂肿瘤异质性方面的独特价值，并前瞻性地讨论了多组学整合与虚拟染色技术在提升数据可扩展性方面的潜力。文章创新性地提出了2D与3D互补的混合策略，为在计算病理学背景下更全面地理解肿瘤架构提供了重要的理论指导和实践框架。

---

## 12. 脂质代谢重编程在塑造肿瘤免疫微环境中的多样化作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41396133)
**期刊：** Cancer research
**PMID：** 41396133
**DOI：** 10.1158/0008-5472.CAN-25-2568

### 第一部分 原文与翻译

**英文原标题：** The Diverse Roles of Lipid Metabolism Reprogramming in Shaping the Tumor Immune Microenvironment.

> **英文摘要：**
> Lipid metabolism reprogramming modulates the tumor microenvironment (TME) and alters the function of immune cells, including tumor-infiltrating lymphocytes (TIL). Although lipids can enhance general T-cell activity, high lipid content in the TME may restrain the antitumor function of effector T cells and augment immunosuppression by regulatory T cells. In addition, lipid metabolism reprogramming greatly influences the cross-talk between TILs and other immune cells in the TME, including dendritic cells, macrophages, and myeloid-derived suppressor cells. By discussing potential therapeutic strategies to target lipid metabolism in TILs, along with combination approaches with chemo-immunotherapy, nanomedicine, and adoptive cell transfer therapy, we aim to lay the groundwork for advancing effective treatments for patients with cancer.

> **中文摘要：**
> 脂质代谢重编程调节肿瘤微环境（TME）并改变免疫细胞的功能，包括肿瘤浸润淋巴细胞（TIL）。尽管脂质可以增强常规T细胞活性，但TME中的高脂质含量可能会抑制效应T细胞的抗肿瘤功能，并增强调节性T细胞介导的免疫抑制。此外，脂质代谢重编程极大影响了TIL与TME中其他免疫细胞（包括树突状细胞、巨噬细胞和髓源性抑制细胞）之间的相互作用。通过探讨针对TIL中脂质代谢的潜在治疗策略，以及与化学免疫疗法、纳米药物和过继细胞转移疗法的联合应用方案，我们旨在为推进癌症患者的有效治疗奠定基础。

### 第二部分 AI 大师评价

本文综述了脂质代谢重编程在肿瘤免疫微环境（TME）中的多重调控机制，重点阐述了脂质积聚如何导致效应T细胞功能受损及增强免疫抑制性细胞的活性。文章不仅揭示了代谢重构对不同免疫亚群互作的影响，还创新性地提出了将脂质代谢靶向药物与免疫疗法及纳米医学结合的联合策略。该评价对于理解肿瘤代谢耐药机制并开发新型肿瘤免疫治疗方案具有重要的理论参考价值。

---

## 13. p300催化抑制优先针对多发性骨髓瘤中IRF4的致癌活性和肿瘤生长

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41248492)
**期刊：** Cancer research
**PMID：** 41248492
**DOI：** 10.1158/0008-5472.CAN-25-3440

### 第一部分 原文与翻译

**英文原标题：** Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma.

> **英文摘要：**
> UNLABELLED: The oncogenic transcription factor (TF) IRF4 is a currently undrugged universal multiple myeloma dependency. Using transcriptional regulatory network mapping, an unbiased multiomics target ID approach, we identified the coactivator lysine acetyltransferase (KAT) p300 as a key IRF4 partner. Validation of this preferential relationship through quantitative interactome mapping revealed that IRF4 was the most abundant multiple myeloma-specific dependency and more closely complexed with p300 than other TFs, such as IKZF1/IKZF3. Development of optimized p300 KAT inhibitors enabled inhibition of IRF4 activity and multiple myeloma proliferation ex vivo and in vivo. p300/CBP KAT inhibition preferentially targeted multiple myeloma cells over normal cells, specifically modulating the multiple myeloma transcriptome, and the p300 KAT inhibitors more completely inhibited IRF4 activity at lower levels compared with existing p300/CREB-binding protein (CBP) bromodomain inhibitors. Furthermore, combining p300/CBP KAT inhibition and therapeutics with orthogonal mechanisms targeting transcription in multiple myeloma elicited synergistic antitumor effects. Together, these data motivate the ongoing clinical development of p300/CBP KAT inhibition in multiple myeloma.
> 
> SIGNIFICANCE: Inhibition of p300 lysine acetyltransferase activity preferentially modulates the IRF4 transcriptional regulatory network and is orthogonal to mechanisms of multiple myeloma standard-of-care treatment, supporting the translational potential of p300 inhibitors.

> **中文摘要：**
> 致癌转录因子 (TF) IRF4 是目前多发性骨髓瘤中一种尚未被药物攻克的普遍依赖性靶点。通过转录调控网络图谱分析（一种无偏倚的多组学靶点鉴定方法），我们鉴定出共激活因子赖氨酸乙酰转移酶 (KAT) p300 是 IRF4 的关键伙伴。通过定量互作组图谱验证了这种优先关系，结果显示 IRF4 是最丰富的多发性骨髓瘤特异性依赖物，并且与其他转录因子（如 IKZF1/IKZF3）相比，与 p300 的复合物结合更为紧密。优化后的 p300 KAT 抑制剂的研发实现了在离体和体内环境下对 IRF4 活性和多发性骨髓瘤增殖的抑制。p300/CBP KAT 抑制优先针对多发性骨髓瘤细胞而非正常细胞，特异性地调节多发性骨髓瘤的转录组，且与现有的 p300/CREB 结合蛋白 (CBP) 溴结构域抑制剂相比，p300 KAT 抑制剂在较低剂量下能更完全地抑制 IRF4 活性。此外，将 p300/CBP KAT 抑制与针对多发性骨髓瘤转录的正交机制疗法相结合，产生了协同的抗肿瘤效应。总之，这些数据推动了目前 p300/CBP KAT 抑制在多发性骨髓瘤中的临床开发。意义：抑制 p300 赖氨酸乙酰转移酶活性可优先调节 IRF4 转录调控网络，并与多发性骨髓瘤的标准治疗机制互补，支持了 p300 抑制剂的转化潜力。

### 第二部分 AI 大师评价

本研究通过多组学整合分析精准锁定了多发性骨髓瘤核心致癌因子IRF4的关键协同蛋白p300，并证明了催化结构域抑制剂在阻断IRF4网络方面优于现有的溴结构域抑制剂。研究不仅揭示了p300作为IRF4成药靶点的高选择性，还展示了其与标准疗法的协同增效作用。该成果为针对“不可成药”转录因子的精准治疗提供了坚实的理论支撑和临床转化路径。

---

## 14. 由 BMP2/4-ACVR1 信号介导的促肿瘤巨噬细胞极化在肿瘤起始阶段调控免疫抑制微环境

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41248425)
**期刊：** Cancer research
**PMID：** 41248425
**DOI：** 10.1158/0008-5472.CAN-24-4392

### 第一部分 原文与翻译

**英文原标题：** Protumor Macrophage Polarization Mediated by BMP2/4-ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation.

> **英文摘要：**
> UNLABELLED: Cancer cells are able to evade immunosurveillance by engendering an immunosuppressive "cold" tumor microenvironment (cTME). A better understanding of the mechanisms underlying the establishment of a cTME in the initial phases of tumor formation could help uncover improved immunotherapeutic strategies. To characterize the temporal dynamics of the formation of a cTME, we generated single-cell RNA sequencing data during the initiation phases of EGFR-driven lung adenocarcinoma. Macrophages in the tumor microenvironment (TME) underwent a state transition from antitumor macrophages to protumor macrophages, which orchestrated the formation of a cTME. Tumor cell-derived BMP2/4 induced the polarization of protumor macrophages, and inhibiting the BMP2/4-ACVR1 axis with an ACVR1 inhibitor converted the cTME into a "hot" TME, resulting in a potent suppression of tumor growth. Furthermore, patients with EGFR-mutant lung adenocarcinoma exhibited similar cTME characteristics to those observed in mice, and high expression of ACVR1 correlated with worse patient prognosis. Overall, in addition to elucidating the role of protumor macrophages in cTME formation, this study pinpoints targeting ACVR1 as a therapeutic strategy for treating EGFR-mutant lung cancers. SIGNIFICANCE: In the early stages of lung cancer development, cancer cells reprogram tumor-associated macrophages via BMP2/4-ACVR1 signaling to stimulate the formation of an immunosuppressive tumor microenvironment, establishing ACVR1 as a potential immunotherapeutic target.

> **中文摘要：**
> 未标注：癌细胞能够通过产生免疫抑制性的“冷”肿瘤微环境（cTME）来逃避免疫监视。深入了解肿瘤形成初始阶段 cTME 建立的潜在机制，有助于发现更有效的免疫治疗策略。为了表征 cTME 形成的动态变化，我们在 EGFR 驱动的肺腺癌起始阶段生成了单细胞 RNA 测序数据。肿瘤微环境（TME）中的巨噬细胞经历了从抗肿瘤巨噬细胞向促肿瘤巨噬细胞的状态转变，这主导了 cTME 的形成。肿瘤细胞衍生的 BMP2/4 诱导了促肿瘤巨噬细胞的极化，使用 ACVR1 抑制剂阻断 BMP2/4-ACVR1 轴可将 cTME 转化为“热”TME，从而产生强效的肿瘤生长抑制作用。此外，EGFR 突变型肺腺癌患者表现出与小鼠观察到的相似的 cTME 特征，且 ACVR1 的高表达与患者预后较差相关。总之，本研究不仅阐明了促肿瘤巨噬细胞在 cTME 形成中的作用，还指出靶向 ACVR1 是治疗 EGFR 突变型肺癌的一种治疗策略。意义：在肺癌发展的早期阶段，癌细胞通过 BMP2/4-ACVR1 信号重编程肿瘤相关巨噬细胞，刺激免疫抑制性肿瘤微环境的形成，确立了 ACVR1 作为一个潜在的免疫治疗靶点。

### 第二部分 AI 大师评价

该研究通过单细胞测序技术揭示了EGFR驱动肺腺癌在起始阶段cTME形成的动态过程，重点发现了BMP2/4-ACVR1信号轴在驱动巨噬细胞向促肿瘤表型极化中的关键作用。通过使用ACVR1抑制剂成功将“冷”肿瘤转化为“热”肿瘤并抑制肿瘤生长，为解决EGFR突变肺癌的免疫治疗耐药提供了新靶点。研究结合了转基因小鼠模型与临床患者数据验证，具有很高的科学价值和临床转化潜力。

---

## 15. 线粒体转移通过恢复呼吸作用支持从头嘧啶生物合成及肿瘤进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41248423)
**期刊：** Cancer research
**PMID：** 41248423
**DOI：** 10.1158/0008-5472.CAN-24-0737

### 第一部分 原文与翻译

**英文原标题：** Mitochondrial Transfer Rescues Respiration to Support De Novo Pyrimidine Biosynthesis and Tumor Progression.

> **英文摘要：**
> UNLABELLED: Cancer cells with severe defects in mitochondrial DNA (mtDNA) can import mitochondria via horizontal mitochondrial transfer to restore respiration. Mitochondrial respiration is necessary for the activity of dihydroorotate dehydrogenase (DHODH), an enzyme of the inner mitochondrial membrane that catalyzes the fourth step of de novo pyrimidine synthesis. In this study, we investigated the role of de novo synthesis of pyrimidines in driving tumor growth in mtDNA-deficient (ρ0) cells. Although ρ0 cells grafted in mice readily acquired mtDNA, this process was delayed in cells transfected with alternative oxidase (AOX), which combines the functions of mitochondrial respiratory complexes III and IV. The ρ0 AOX cells were glycolytic but maintained normal DHODH activity and pyrimidine production. Deletion of DHODH in a panel of tumor cells completely blocked or delayed tumor growth. The grafted ρ0 cells rapidly recruited tumor-promoting/stabilizing cells of the innate immune system, including protumor M2 macrophages, neutrophils, eosinophils, and mesenchymal stromal cells (MSC). The ρ0 cells recruited MSCs early after grafting, which were potential mitochondrial donors. Grafting MSCs together with ρ0 cancer cells into mice resulted in mitochondrial transfer from MSCs to cancer cells. Overall, these findings indicate that cancer cells with compromised mitochondrial function readily acquire mtDNA from other cells in the tumor microenvironment to restore DHODH-dependent respiration and de novo pyrimidine synthesis. The inhibition of tumor growth induced by blocking DHODH supports targeting pyrimidine synthesis as a potential widely applicable therapeutic approach. SIGNIFICANCE: Mitochondrial complexes III and IV promote tumor progression by supporting de novo pyrimidine synthesis, requiring cancer cells devoid of mitochondrial DNA to recruit mitochondria from source cells to restore respiration in order to form tumors.

> **中文摘要：**
> 未标记：具有严重线粒体DNA（mtDNA）缺陷的癌细胞可以通过水平线粒体转移导入线粒体，以恢复呼吸作用。线粒体呼吸对于二氢乳清酸脱氢酶（DHODH）的活性是必需的，DHODH是一种位于线粒体内膜的酶，负责催化从头嘧啶合成的第四步。在本研究中，我们探讨了从头嘧啶合成在驱动mtDNA缺陷（ρ0）细胞肿瘤生长中的作用。尽管移植到小鼠体内的ρ0细胞很容易获得mtDNA，但在转染了替代氧化酶（AOX）的细胞中，这一过程被延迟，AOX结合了线粒体呼吸复合物III和IV的功能。ρ0 AOX细胞呈现糖酵解特性，但保持了正常的DHODH活性和嘧啶产量。在一组肿瘤细胞中缺失DHODH可完全阻断或延迟肿瘤生长。移植的ρ0细胞迅速招募了先天免疫系统的促肿瘤/稳定细胞，包括促肿瘤M2型巨噬细胞、中性粒细胞、嗜酸性粒细胞和间充质基质细胞（MSC）。ρ0细胞在移植后早期即招募了MSC，后者是潜在的线粒体供体。将MSC与ρ0癌细胞共同移植到小鼠体内，导致线粒体从MSC转移至癌细胞。总的来说，这些发现表明，线粒体功能受损的癌细胞可以轻易从肿瘤微环境中的其他细胞获取mtDNA，以恢复DHODH依赖性呼吸和从头嘧啶合成。阻断DHODH诱导的肿瘤生长抑制作用，支持将靶向嘧啶合成作为一种潜在且广泛适用的治疗方法。意义：线粒体复合物III和IV通过支持从头嘧啶合成来促进肿瘤进展，这使得缺乏线粒体DNA的癌细胞必须从供体细胞招募线粒体以恢复呼吸，从而形成肿瘤。

### 第二部分 AI 大师评价

本研究揭示了线粒体DNA（mtDNA）缺陷癌细胞通过从肿瘤微环境（尤其是间充质基质细胞）招募线粒体来恢复呼吸链功能的代偿机制。核心发现是，这种线粒体转移的关键驱动力是为了维持DHODH介导的从头嘧啶合成，而非单纯的能量供应。通过引入替代氧化酶（AOX）的对比实验，研究巧妙地证明了呼吸链与核苷酸代谢在肿瘤形成中的关键偶联关系，为靶向嘧啶合成路径治疗代谢受损型癌症提供了坚实的理论依据。

---

## 16. CRISPR-Cas9筛选鉴定胰腺癌中KRAS抑制的耐药机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41248420)
**期刊：** Cancer research
**PMID：** 41248420
**DOI：** 10.1158/0008-5472.CAN-25-1835

### 第一部分 原文与翻译

**英文原标题：** CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

> **英文摘要：**
> UNLABELLED: KRAS inhibitors (KRASi) targeting various KRAS mutations have entered clinical trials for pancreatic cancer. Despite promising preliminary clinical responses, most patients relapse due to intrinsic or acquired resistance. Thus, combination treatments are essential to extend the efficacy of KRAS-targeted therapies. To further determine the genetic mechanisms of KRASi resistance, we performed KRASi-anchored CRISPR-Cas9 loss-of-function screens in KRASG12D-, KRASG12C-, KRASG12R-, and KRASQ61H-mutant pancreatic ductal adenocarcinoma (PDAC) cell lines, using six KRASi, to identify genes that modulate sensitivity to KRAS inhibition. Several hits from the screens, including EGFR, CK2, p110α, p110γ, and YAP, were validated by combining targeted inhibitors with KRASi. KRASQ61H-mutant PDAC cell lines were intrinsically less dependent on KRAS for survival than other KRAS mutational subtypes. Furthermore, the EGFR inhibitor erlotinib synergized with the RAS(ON) multiselective inhibitor RMC-7977 in KRASQ61H-mutant PDAC cell lines and in cell lines with highly active EGFR by mitigating ERK rebound activity. KRASi-resistant cell lines featured sustained ERK/MAPK dependence despite decreased ERK activity. Together, these findings enhance the understanding of intrinsic and acquired resistance to KRASi and identify therapeutic vulnerabilities that can potentially be exploited for KRASi combination therapies in patients with pancreatic cancer. SIGNIFICANCE: A comprehensive assessment of genetic modulators of KRAS inhibitor sensitivity identifies combination approaches to increase the efficacy of KRAS inhibitors and demonstrates the limited response of KRASQ61H-mutant cancer cells to KRAS inhibition.

> **中文摘要：**
> 未标注部分：针对多种KRAS突变的KRAS抑制剂（KRASi）已进入胰腺癌临床试验阶段。尽管初步临床反应令人鼓舞，但大多数患者因内在或获得性耐药而复发。因此，联合治疗对于延长KRAS靶向疗法的疗效至关重要。为了进一步确定KRASi耐药的遗传机制，我们在KRASG12D、KRASG12C、KRASG12R和KRASQ61H突变的胰腺导管腺癌（PDAC）细胞系中，利用六种KRASi进行了以KRASi为锚点的CRISPR-Cas9功能缺失筛选，旨在鉴定调节KRAS抑制敏感性的基因。筛选出的几个关键基因，包括EGFR、CK2、p110α、p110γ和YAP，通过将靶向抑制剂与KRASi联合使用得到了验证。与其他KRAS突变亚型相比，KRASQ61H突变的PDAC细胞系在生存上对KRAS的内在依赖性较低。此外，EGFR抑制剂厄洛替尼与RAS(ON)多选择性抑制剂RMC-7977在KRASQ61H突变的PDAC细胞系以及EGFR高度活跃的细胞系中，通过减轻ERK反弹活性发挥了协同作用。尽管ERK活性降低，但KRASi耐药细胞系表现出持续的ERK/MAPK依赖性。总之，这些发现增强了对KRASi内在和获得性耐药的理解，并确定了可用于胰腺癌患者KRASi联合治疗的潜在治疗靶点。意义：对KRAS抑制剂敏感性的遗传调节因子进行全面评估，确定了提高KRAS抑制剂疗效的联合方案，并证明了KRASQ61H突变的癌细胞对KRAS抑制的反应有限。

### 第二部分 AI 大师评价

本研究通过大规模CRISPR-Cas9功能缺失筛选，系统性地揭示了胰腺癌对不同KRAS突变抑制剂产生耐药的遗传机制。研究不仅识别出EGFR、CK2及PI3K亚基等关键耐药旁路，还特别发现KRASQ61H亚型对KRAS抑制表现出独特的低依赖性。通过联合应用EGFR抑制剂有效阻断了ERK反馈激活，该研究为克服KRAS抑制剂的耐药性提供了坚实的实验依据，并为临床开发精准的联合用药策略指明了方向。

---

## 17. 衰老微环境是胰腺癌免疫排除和转移命运的决定因素

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41202211)
**期刊：** Cancer research
**PMID：** 41202211
**DOI：** 10.1158/0008-5472.CAN-25-1904

### 第一部分 原文与翻译

**英文原标题：** The Aging Microenvironment Is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer.

> **英文摘要：**
> UNLABELLED: Aging is a critical yet understudied determinant in pancreatic ductal adenocarcinoma (PDAC) risk and outcomes. Despite a strong epidemiologic association with age, conventional PDAC preclinical models fail to capture the histopathologic and stromal complexities that emerge in older organisms. Using an age-relevant syngeneic orthotopic model, we demonstrated that organismal aging accelerates PDAC progression and metastasis. Transcriptomic and secretome profiling identified a conserved extracellular matrix gene signature enriched in cancer-associated fibroblasts (CAF) from aged tumors, consistent with an augmented fibrotic landscape that supports immunosuppression, metastatic tropism, and poor prognosis. Direct testing of the functional impact of stromal aging in heterochronic co-implantation models revealed that revitalizing the aged tumor stroma with young CAFs restores immune infiltration and attenuates metastasis in older hosts. Conversely, aged CAFs, although immunosuppressive, failed to enhance metastasis in young hosts, suggesting that a youthful microenvironment exerts dominant regulatory control over disease progression. These findings demonstrate that stromal age is a critical modulator of both immune exclusion and metastatic behavior in PDAC. Importantly, this work establishes a conceptual framework for understanding how aging shapes the tumor microenvironment in PDAC and opens a fertile avenue of investigation into age-specific stromal regulation. Moreover, these findings raise compelling questions about the underlying molecular mechanisms and lay the foundation for future efforts to therapeutically target stromal aging in PDAC.
> 
> SIGNIFICANCE: Age-dependent stromal changes drive progression of pancreatic cancer, linking aging, stromal remodeling, and tumor aggressiveness and suggesting that rejuvenating the aged microenvironment may improve outcomes in older patients.

> **中文摘要：**
> 未标注：衰老是胰腺导管腺癌（PDAC）风险和预后中一个关键但尚未得到充分研究的决定因素。尽管与年龄存在强烈的流行病学关联，但传统的PDAC临床前模型未能捕捉到老年生物体中出现的组织病理学和基质复杂性。利用与年龄相关的同基因原位模型，我们证明了生物体衰老加速了PDAC的进展和转移。转录组和分泌组谱分析确定了一个保守的细胞外基质基因特征，该特征在老年肿瘤的癌相关成纤维细胞（CAF）中富集，这与支持免疫抑制、转移趋向性和不良预后的增强纤维化景观相一致。在异时共移植模型中对基质衰老功能影响的直接测试表明，用年轻的CAF使老化的肿瘤基质恢复活力，可以恢复老年宿主的免疫浸润并减轻转移。相反，尽管老化的CAF具有免疫抑制作用，但未能增强年轻宿主的转移，这表明年轻的微环境对疾病进展发挥着主导性的调节控制。这些发现表明，基质年龄是PDAC中免疫排除和转移行为的关键调节因子。重要的是，这项工作建立了一个理解衰老如何塑造PDAC肿瘤微环境的概念框架，并为年龄特异性基质调节的研究开辟了广阔前景。此外，这些发现提出了关于潜在分子机制的引人深思的问题，并为未来在PDAC中以基质衰老为治疗目标的努力奠定了基础。
> 
> 意义：年龄依赖性的基质变化驱动了胰腺癌的进展，将衰老、基质重塑和肿瘤侵袭性联系起来，并表明使衰老的微环境恢复活力可能会改善老年患者的预后。

### 第二部分 AI 大师评价

本研究通过构建年龄相关的原位PDAC模型，深刻揭示了衰老微环境在驱动肿瘤进展、免疫排除及转移中的核心作用。研究创新性地发现老年肿瘤中CAF的细胞外基质特征发生了显著改变，且通过引入年轻CAF可逆转老年宿主的免疫抑制并抑制转移。这一发现不仅打破了传统模型忽略年龄因素的局限，还为开发针对基质衰老的靶向疗法、改善老年胰腺癌患者预后提供了坚实的实验证据和理论框架。

---

速递结束，祝您工作愉快！